A seleno-hormetine protects bone marrow hematopoietic cells against ionizing radiation-induced toxicities.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
24
09
2018
accepted:
28
03
2019
entrez:
30
4
2019
pubmed:
30
4
2019
medline:
18
12
2019
Statut:
epublish
Résumé
2,2'-diselenyldibenzoic acid (DSBA) is a chemical probe produced to explore the pharmacological properties of diphenyldiselenide-derived agents with seleno-hormetic activity undergoing preclinical development. The present study was designed to verify in vivo the drug's properties and to determine mechanistically how these may mediate the protection of tissues against stress conditions, exemplified by ionizing radiation induced damage in mouse bone marrow. In murine bone marrow hematopoietic cells, the drug initiated the activation of the Nrf2 transcription factor resulting in enhanced expression of downstream stress response genes. This type of response was confirmed in human liver cells and included enhanced expression of glutathione S-transferases (GST), important in the metabolism and pharmacological function of seleno-compounds. In C57 BL/6 mice, DSBA prevented the suppression of bone marrow hematopoietic cells caused by ionizing radiation exposure. Such in vivo prevention effects were associated with Nrf2 pathway activation in both bone marrow cells and liver tissue. These findings demonstrated for the first time the pharmacological properties of DSBA in vivo, suggesting a practical application for this type of Se-hormetic molecules as a radioprotective and/or prevention agents in cancer treatments.
Identifiants
pubmed: 31034521
doi: 10.1371/journal.pone.0205626
pii: PONE-D-18-27820
pmc: PMC6488049
doi:
Substances chimiques
Benzene Derivatives
0
NF-E2-Related Factor 2
0
NFE2L2 protein, human
0
Nfe2l2 protein, mouse
0
Organoselenium Compounds
0
Radiation-Protective Agents
0
diphenyldiselenide
1666-13-3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0205626Subventions
Organisme : NCRR NIH HHS
ID : P20 RR024485
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Blood. 2006 Jan 1;107(1):358-66
pubmed: 16150936
Free Radic Biol Med. 2015 Nov;88(Pt B):108-146
pubmed: 26122708
Cancer Res. 2017 Dec 1;77(23):6641-6650
pubmed: 28951456
Free Radic Biol Med. 2011 Jul 1;51(1):30-7
pubmed: 21565268
J Am Chem Soc. 2011 Sep 7;133(35):14109-19
pubmed: 21786801
Free Radic Biol Med. 2018 May 20;120:204-216
pubmed: 29578070
Biochem Pharmacol. 1994 Mar 15;47(6):1007-12
pubmed: 8147899
J Biol Chem. 2009 Jan 2;284(1):436-45
pubmed: 18990698
Free Radic Biol Med. 2015 Jan;78:56-65
pubmed: 25452145
Radiat Res. 2011 Dec;176(6):743-52
pubmed: 22014293
Cancer Res. 1994 Aug 15;54(16):4313-20
pubmed: 8044778
Biofactors. 2019 Mar;45(2):152-168
pubmed: 30561781
Stem Cells Dev. 2015 Jun 1;24(11):1342-51
pubmed: 25603016
Cancer Treat Rev. 2010 May;36(3):268-75
pubmed: 20044209
PLoS One. 2014 May 02;9(5):e95968
pubmed: 24788761
Biochim Biophys Acta Gen Subj. 2019 Jan;1863(1):130-143
pubmed: 30290218
Semin Oncol. 1999 Apr;26(2 Suppl 7):95-101
pubmed: 10348267
Free Radic Res. 2010 Jul;44(7):721-33
pubmed: 20528574
Free Radic Biol Med. 2015 Nov;88(Pt B):466-480
pubmed: 26151571
Adv Cancer Res. 2017;136:259-302
pubmed: 29054421
Free Radic Biol Med. 2010 Jan 15;48(2):348-56
pubmed: 19925862
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Apr 15;1019:29-44
pubmed: 26922696
PLoS One. 2014 Sep 12;9(9):e107478
pubmed: 25216273
Biochem Mol Biol Int. 1994 Feb;32(2):291-8
pubmed: 8019434
Oncotarget. 2017 Jul 15;8(41):69797-69807
pubmed: 29050242
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Oct 15;877(28):3467-74
pubmed: 19443279
J Biol Chem. 2018 Mar 23;293(12):4366-4380
pubmed: 29374060
FEBS Lett. 2016 May;590(10):1455-66
pubmed: 27086966
Redox Biol. 2018 Jul;17:171-179
pubmed: 29702404